Dublin - Cosmo Pharmaceuticals N.V. (SIX: COPN), a specialty pharmaceutical company leader in the field of selected gastrointestinal disorders and endoscopy, announced today the publication of a review of Aemcolo, the Company's broad-spectrum oral antibiotic, in a Clinical Drug Investigation that highlights its safety, effectiveness and advantages over other treatment options.
The review concludes that Aemcolo, due to Cosmo's proprietary MMX technology delivering the active drug substance directly to the colon and minimizing its systemic absorption, represents an effective and well tolerated treatment option for non-dysenteric traveler's diarrhea (TD) in adults.
'This review highlights the effectiveness and safety of Aemcolo for non-dysenteric diarrhea, as well as its potential advantages over other treatment options. The publication is timely, particularly with the recent ban of chinolonic antibiotics for this indication by EU and US regulators, which opens up a greater market opportunity for Aemcolo. We are now focusing on expanding the benefits of this product beyond the currently approved indication,' says Luigi Moro, Chief Scientific Officer of Cosmo Pharmaceuticals.
In particular, the review highlighted that adult patients in two Phase 3 studies treated with Aemcolo experienced a shorter duration of non-dysenteric traveler's diarrhea. In addition, patients treated with ciprofloxacin exhibited a significant increase in the colonization rate by Extended Spectrum -Lactamase-producing (ESBL) Escherichia Coli, whereas patients treated with Aemcolo did not. ESBL are enzymes that confer resistance to most beta-lactam antibiotics, including penicillins, cephalosporins and the monobactam aztreonam. This characteristic of Aemcolo provides an important advantage in view of the global concerns regarding the emergence of multi-drug resistant bacteria, which cause infections that are challenging to treat.
The application of Cosmo's MMX technology to Rifamycin SV to create Aemcolo allows the antibiotic to be delivered directly into the colon, thereby avoiding unwanted effects on the beneficial bacterial flora living in the upper portions of the gastro-intestinal tract. The specific dissolution profile of Aemcolo tablets is also thought to increase the colonic delivery of the antibiotic so that an optimized intestinal concentration is achieved and systemic absorption in the small intestine is avoided.
About Cosmo Pharmaceuticals
Cosmo is a specialty pharmaceutical company focused in treating selected Gastrointestinal Disorders and Endoscopy. The Company's proprietary clinical development pipeline specifically addresses innovative treatments for IBD, Colonic Infections and detection of colonic lesions. Cosmo has also developed medical devices for endoscopy and has recently entered into a partnership with Medtronic for the global distribution of its novel Artificial Intelligence device to be used in coloscopies and GI procedures. Further, Cosmo is the licensee for US of the novel agent for procedural sedation, Remimazolam.
Tel: +353 (1) 8170 370
Some of the information contained in this press release contains forward-looking statements. Readers are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Cosmo undertakes no obligation to publicly update or revise any forward-looking statements.
This communication is not an offer of securities of any issuer. Securities may not be offered or sold in the United States absent registration or an exemption from the registration requirement of the US Securities Act of 1933.
The offer will be made solely by means of, and on the basis of, a securities prospectus to be published. An investment decision regarding the securities to be publicly offered should only be made on the basis of the securities prospectus.
This press release is made to and directed only at (i) persons outside the United Kingdom, (ii) investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the 'Order'), and (iii) high net worth individuals, and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d) of the Order. Any person who is not a relevant person should not act or rely on this press release or any of its contents.
This press release does not constitute an 'offer of securities to the public' within the meaning of Directive 2003/71/EC of the European Union (the 'Prospectus Directive') of the securities referred to in it (the 'Securities') in any member state of the European Economic Area (the 'EEA'). Any offers of the Securities to persons in the EEA will be made pursuant to an exemption under the Prospectus Directive, as implemented in member states of the EEA, from the requirement to produce a prospectus for offers of the Securities.